FDA-Drug2026-07-29Class IIPROCESSING DEFECT

Fresenius Kabi Naropin injection recalled for hair contamination

Nationwide distribution

Fresenius Kabi Naropin recalled for particulate matter

Hair was found in Naropin (ropivacaine hydrochloride) injection vials used for local anesthesia. The affected product is the 0.5% concentration in 20 mL single-dose vials. Approximately 92,600 vials from Lot #6133436 (expiration 10/2028) were distributed nationwide.

  • If you have Naropin from the affected lot, do not use it.
  • Contact Fresenius Kabi or your healthcare provider with questions about replacement or alternatives.
  • Healthcare facilities should quarantine and return affected vials to the manufacturer.
Hazard

Presence of Particulate Matter: Hair was found in products

Sold states
Nationwide within in the USA
Affected count
92,600 vials
Manufactured in
3 Corporate Dr, N/A, Lake Zurich, IL, United States
Products
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0727-2026

More Fresenius Kabi USA, LLC recalls

Don't want to check this manually?

We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Get the Sunday Brief